Disc Medicine (NASDAQ:IRON) Price Target Raised to $75.00

Disc Medicine (NASDAQ:IRON) had its price target increased by Scotiabank from $73.00 to $75.00 in a report issued on Monday,Benzinga reports. The firm currently has a sector outperform rating on the stock.

Several other analysts have also recently issued reports on the stock. Stifel Nicolaus increased their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Raymond James upgraded shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. TD Cowen started coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating on the stock. Wedbush reiterated an “outperform” rating and issued a $90.00 target price (up from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $118.00 target price on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Disc Medicine has a consensus rating of “Buy” and an average price target of $89.10.

Disc Medicine Trading Down 3.3 %

Shares of IRON stock opened at $54.33 on Monday. The stock has a market capitalization of $1.62 billion, a P/E ratio of -13.65 and a beta of 0.73. The firm’s 50 day moving average is $57.89 and its 200 day moving average is $55.70. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.08. On average, equities analysts predict that Disc Medicine will post -4.07 EPS for the current year.

Insider Activity at Disc Medicine

In other Disc Medicine news, insider Rahul Khara sold 7,500 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $62.75, for a total transaction of $470,625.00. Following the completion of the sale, the insider now owns 14,035 shares of the company’s stock, valued at $880,696.25. This represents a 34.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO John D. Quisel sold 12,791 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $66.01, for a total transaction of $844,333.91. Following the sale, the chief executive officer now directly owns 72,065 shares of the company’s stock, valued at $4,757,010.65. The trade was a 15.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 74,080 shares of company stock valued at $4,523,520. Insiders own 4.24% of the company’s stock.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its position in Disc Medicine by 798.4% during the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock valued at $36,000 after buying an additional 503 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Disc Medicine during the 4th quarter valued at $40,000. Tower Research Capital LLC TRC boosted its position in Disc Medicine by 47.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock valued at $52,000 after buying an additional 266 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock valued at $54,000 after buying an additional 337 shares during the period. Finally, Quest Partners LLC purchased a new stake in Disc Medicine during the 3rd quarter valued at $131,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.